Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma

Oncology
2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
2100%

Competitive Landscape

2 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
mRNA-2752Phase 1RNA Therapeutic
Moderna
ModernaCAMBRIDGE, MA
1 program
1
mRNA-2752Phase 1RNA Therapeutic1 trial
Active Trials
NCT03739931Completed134Est. Aug 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ModernamRNA-2752

Clinical Trials (1)

Total enrollment: 134 patients across 1 trials

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Start: Nov 2018Est. completion: Aug 2025134 patients
Phase 1Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space